On November 7, during the 8th China International Import Expo (CIIE), Novo-Nordisk A/S (NVO.US), a global leader in biopharmaceuticals, hosted the "Boundless Care, New Beginnings" event—the 2025 Novo-Nordisk Health Ecosystem Partner Alliance Summit and NovoCare New Product Launch Ceremony. At the event, Novo-Nordisk announced an expansion and upgrade of its "Health Ecosystem Alliance," established in 2023. As a key strategic partner, FANGZHOU JIANKE (06086) was invited and awarded the "Outstanding Health Ecosystem Strategic Partner" trophy.
One of the highlights at Novo-Nordisk's CIIE exhibition was the debut of its first scientific weight loss experience space, the "Lightness Cabin." Showcasing innovative achievements in the "AI + Weight Loss" sector, FANGZHOU JIANKE's Jianke Doctor APP unveiled its new application scenario—the "AI Weight Loss Consultant"—drawing significant attention and praise from attendees. The "AI Weight Loss Consultant" covers the entire weight management process, enhancing public awareness of obesity diagnosis, treatment, and long-term management through interactive experiences.
The "Health Ecosystem Alliance" serves as a platform for mutual growth and collaboration among partners. As a core member, FANGZHOU JIANKE shares Novo-Nordisk's vision for digital chronic disease management. In July 2025, the two companies signed a strategic memorandum to integrate services and demand through innovative digital solutions, empowering both industry stakeholders and patients. Moving forward, they aim to jointly develop a digital chronic disease management ecosystem.
With rising awareness of personal health responsibility, chronic disease management has shifted toward early screening, detection, and intervention. Obesity, a major contributor to cardiovascular diseases and diabetes, has prompted national action, including the 2024 "Weight Management Year" initiative by China's National Health Commission. Recognizing the broader impact of weight management, FANGZHOU JIANKE has pioneered AI-driven solutions in this field, becoming a key player in the "Healthy China · AI + Weight Management" campaign.
Beyond weight management, FANGZHOU JIANKE has also focused on diabetes prevention, leveraging its AI capabilities to gain recognition from Novo-Nordisk. Their collaboration, combining FANGZHOU JIANKE's AI services and Novo-Nordisk's expertise in diabetes and obesity treatment, aims to transition from disease-centered to health-centered care. Novo-Nordisk views this partnership as a model for integrating digital innovation with chronic disease management.
Recent policy support, including China's "AI + Healthcare" development guidelines, has further accelerated industry collaboration. Novo-Nordisk's Senior Vice President and Greater China President emphasized the role of digital innovation in improving public health literacy. Meanwhile, FANGZHOU JIANKE's CEO, Dr. Xie Fangmin, highlighted the need for AI-driven value creation across the chronic disease management chain.
Since 2025, FANGZHOU JIANKE has expanded its "AI + Chronic Disease Management" ecosystem, driving the industry toward systematic and intelligent services. The company remains committed to open collaboration, enhancing the efficiency and quality of internet-based healthcare and chronic disease management to support China's health strategy.